Organization | Kamada, Ltd.

Kamada, Ltd. Report issue

For profit Phase 2 Phase 3

Founded: Rehovot Israel (1990)

Organization Overview

First Clinical Trial

2007

NCT00460096

First Marketed Drug

1990

cytomegalovirus immune globulin intravenous (human) (cytogam)

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Kamada Ltd. | Kamada, Ltd.

Active Ingredients

Marketed Drugs (5)

cytomegalovirus immune globulin intravenous (human) (cytogam) (1990)

hepatitis b immune globulin (human) (BayHep B) (2006)

rabies immune globulin (human) (HyperRAB) (2017)

Rho(D) Immune Globulin Intravenous (Human) (WinRho) (1996)

varicella zoster immune globulin (human) (varizig) (2012)

Drugs in Phase 3 Trials (5)

albumin (Human) (Plasbumin) (1 trial)

alpha-1 antitrypsin (Prolastin) (11 trials)

methylprednisolone (medrol) (1 trial)

rabies immune globulin (human) (HyperRAB) (2 trials)

rabies vaccine (purified chick embryo cell vaccine) (RabAvert) (1 trial)

Drugs in Phase 2 Trials (1)

COVID-19 convalescent plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

alpha 1-Antitrypsin Deficiency (Phase 3)

Cystic Fibrosis (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Emphysema (Phase 3)

Fibrosis (Phase 2)

Graft vs Host Disease (Phase 3)

Pneumonia (Phase 2)

Pneumonia, Viral (Phase 2)

Pulmonary Emphysema (Phase 3)

Rabies (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 14
# of Trial APIs: 6